Antecedentes de vacunación anti coronavirus de tipo 2 en individuos inmunizados a nivel mundial

Diego Ángel  Jara Gallegos; Sany Sofía  Robledo Galeas; Javier Martín  Reyes Baque

Authors

Diego Ángel Jara Gallegos
Sany Sofía Robledo Galeas
Javier Martín Reyes Baque

Keywords:

SAR COV 2, inherent factors, immunity, antibodies.

Abstract

The coronavirus has convulsed the entire world, which raises the need to investigate the risks it represents for health. The objective of this research work was to systematize the evidence reported regarding the levels of immunization against type 2 coronavirus in immunized individuals worldwide. A bibliographic review was carried out under a qualitative approach of a documentary type with an exploratory descriptive design based on a procedure that implies tracking, organization, systematization and joint analysis of electronic documents on the subject in question, the search strategy that was based on academic profiles was used. accredited to be able to substantiate this article as in the Pubmed, academic Google, Scielo database, using as keywords inherent factors, immunity, antibodies. 37 original and review articles from the last 5 years (2016-2021) were included. Finally, we conclude that the vaccines with the best results according to the levels of antibodies reached were Astra Zeneca, due to its high effectiveness from the second dose 12 weeks after it, the Sinopharm vaccine, had a ninety percent effectiveness 90 days after the second dose, and later when placing the third dose.

Downloads

Download data is not yet available.

References

British Society for Rheumatology. (2021). Recuperado el Abril de 2022, de Principles for COVID-19 vaccination in musculoskeletal and rheumatology for clinicians. : http://www.rheumatology.org.uk/

Beneson S, Oster Y, Cohen Mj, Nir-Paz R. (Marzo de 2021). BNT162b2 mRNA Cobid-19 Vaccine Effectiveness among Health Care Workers. N Engl J Med, 23.

Bernal J, A. N. (2021). Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. medRxiv.

Canadian Rheumatology Association. (2021). Recuperado el Abril de 2022, de Canadian Rheumatology Association recommendation on COVID-19 vaccination in persons with autoimmune rheumatic disease. : http://www.rheum.ca/

Centers for Disease Control. (2020 ). Coronavirus disease 2019 in children - United States. MMWR Morb Mortal Wkly Rep , 69(422-426).

Conforme, H. G. (2021). Eficacia y efectos secundarios de la vacuna Sinovac contra el covid-19 en el Ecuador. . Dominio de las ciencias, 7(5), 16-33.

Curtis J., Johnson A.R., Anthony D.D., Arasaratnam R.J., Baden L.R., Bass A.R. (2021). American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases – version 1. . Arthritis Rheumatol. .

Daniel W, Nivet M, Warner J, Podolsky DK. (2021). Early evidence of the effect of SARS-Cov-2 Vaccine at One Medical Center. N Engl Med.

De Ceano-Vivax M, Martín-Espín I, del Rosal T, Bueno-BarriocanalM, Plata-Gallardo M, Ruiz-Dominguez JA, et al. . (2020 ). SARS-CoV-2 in fection in ambulatory and hospitalized Spanish children. . Arch Dis Child , 105(:808-809).

Escobar Agreda, S. V. (2021). Evidencias preliminares sobre el efecto de vacunación contra la COVID-19 en el Perú. Instituto Nacional de Salud.

Gabriel Chodik, Lilac Tene, Tal Patalon, Sivan Gazit, Amir Ben Tov, Dani Cohen, Khitam Muhsen. (2020). The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after inmunization: real-world evidence. Revista Medica Xiv.

Guijarro C, G. I.-P.-F. (2021). Dramatic drop of new SARS-CoV-2 infections among health care workers after the first dose of the BNT162b2 mRNA Covid-19 Vaccine. medRxiv, 10.

Keehner J, H. L. (2021). SARS-Cov-2 Infection after Vaccination in Health Care Workers in California. N Engl J Med.

Marina Pifano, L. F. (2020). Persistencia de anticuerpos IgG contra SARS-CoV2 en personal de salud - provincia de Buenos Aires. Scielo(https://doi.org/10.1590/SciELOPreprints.1634).

Peach E., Rutter M., Lanyon P., Grainge M.J., Hubbard R., Aston J. (2021). Risk of death among people with rare autoimmune diseases compared to the general population in England during the 2020 COVID-19 pandemic. . Rheumatology (Oxford) , 60(1902-1909).

SER . (2021). Recuperado el Abril de 2022, de Sociedad Española de Reumatología: https://www.ser.es/comunicado-de-la-ser-sobe-la-vacunacion-para-la-covid-19-en-pacientes-con-enfermedades-autoinmunes-sistemicas-eas/

Strangfeld A.S., Schafer M., Gianfrancesco M.A., Lawson-Tovey S., Liew J.W., Ljung L. (2021). Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis.

Tagarro A, Epalza C, Santos M, Sanz-Santaeuremia FJ, Otheo E, Moraleda C, et al. (2020). Screening and severity of COVID-19 in children in Madrid, Spain. . JAMA Pediatr (e201346.).

Vasileiou E, S. C. (Febrero de 2021). Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. SSRN, 19.